Here's What to Expect From HCA Healthcare's Next Earnings Report

Sohini Mondal Barchart Tue Jul 1, 7:14AM CDT
HCA Healthcare Inc sign on building-by JHVEPhoto via Shutterstock

With a market cap of $92.2 billion, HCA Healthcare, Inc. (HCA) is the largest non-governmental operator of acute care hospitals in the United States. Through its subsidiaries, the company owns and operates a broad network of hospitals and healthcare facilities offering comprehensive inpatient, outpatient, and behavioral health services across the U.S. and in England.

The  Nashville, Tennessee-based company is slated to announce its fiscal Q2 2025 earnings results on Tuesday, Jul. 22. Ahead of the event, analysts are expecting HCA to report an EPS of $6.14, an increase of 11.6% from $5.50 in the year-ago quarter. The company has surpassed Wall Street's bottom-line estimates in the past four quarterly reports. In Q1 2025, HCA Healthcare exceeded the consensus EPS estimate by 11.8%.

For fiscal 2025, analysts expect the hospital operator to report EPS of $25.26, up over 15% from $21.96 in fiscal 2024. 

www.barchart.com

Shares of HCA have returned 19.2% over the past 52 weeks, outpacing both the S&P 500 Index's ($SPX) 13.6% rise and the Health Care Select Sector SPDR Fund's (XLV) 7.5% decline over the same period.

www.barchart.com

HCA Healthcare reported Q1 2025 results on Apr. 25, with EPS rising nearly 9% to $6.45, exceeding Wall Street expectations. Revenue also beat forecasts, coming in at $18.3 billion, driven by a 2.6% increase in same-facility admissions and a 4% rise in emergency room visits, reflecting sustained demand for elective and urgent care procedures. Investor confidence was further boosted as HCA reiterated its annual profit forecast of $24.05 to $25.85 per share, despite concerns over tariffs and policy uncertainty. However, the stock fell nearly 4% following the report.

Analysts' consensus rating on HCA Healthcare stock is cautiously optimistic, with a "Moderate Buy" rating overall. Among 25 analysts covering the stock, 15 recommend a "Strong Buy,” two have a "Moderate Buy" rating, and eight give a "Hold" rating. This configuration is slightly less bullish than three months ago, with 16 analysts suggesting a "Strong Buy."

The average analyst price target for HCA is $398.52, indicating a potential upside of just 4% from the current levels.


On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.